RBC Capital Reiterates Outperform on BioCryst Pharma, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has reiterated an Outperform rating on BioCryst Pharma (NASDAQ:BCRX) and maintained a $10 price target.
August 06, 2024 | 12:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has reiterated an Outperform rating on BioCryst Pharma and maintained a $10 price target, indicating continued confidence in the company's performance.
The reiteration of an Outperform rating and the maintenance of a $10 price target by RBC Capital suggests that the analyst has a positive outlook on BioCryst Pharma's future performance. This could lead to increased investor confidence and a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100